Thomas Barreiro

Pain Management


 13225 Sw 88th Ave, Miami
    Florida, 33176-5935

 786-638-3031    Maps & Directions
Thomas Barreiro is a Miami, Florida based physiatrist who is specialized in Pain Management (PM&R). Active license number of Thomas Barreiro as Pain Management (PM&R) is 39614 in Florida.

Thomas Barreiro provides a high level of care, either as a primary physician or consultant, for patients experiencing problems with acute, chronic or cancer pain in both hospital and ambulatory settings. Patient care needs may also be coordinated with other specialists.
Complete Profile:
Thomas Barreiro speciality, credentials, practice address, contact phone number and fax are as below. Patients can directly walk in or can call on the below given phone number for appointment.
Specialization: Pain Management (PM&R)
Gender:Male
Practice Address:13225 Sw 88th Ave, Miami,
Florida, 33176-5935
Phone:786-638-3031
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS). NPI details are as mentioned below.
NPI Number: 1912612532
NPI Enumeration Date: 18 Jan, 2023
NPI Last Update On: 18 Jan, 2023
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Thomas Barreiro are as mentioned below.
License NumberSpecializationStateStatus
39614Pain Management FloridaPrimary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address: 13225 Sw 88th Ave,
Miami, Florida
Zip: 33176-5935
Phone Number: --
Fax Number: --
Patients can reach Thomas Barreiro at 13225 Sw 88th Ave, Miami, Florida or can call to book an appointment on 786-638-3031. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 14 July, 2025.
Comments/ Reviews: